Thus, this single seemingly obscure control point in the Nrf2 activation pathway appears sufficient to decrease Nrf2 activity leading to kidney disease, or to elevate Nrf2 activation in ovarian cancer cells sufficiently to cause resistance to an anticancer drug. This evidence concerns the gene NFE2L2 and ovarian cancer.